NCT06208527 The NADage Study: Nicotinamide Riboside Replenishment Therapy Against Functional Decline in Aging
| NCT ID | NCT06208527 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Haukeland University Hospital |
| Condition | Frailty |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-01 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 100 participants in total. It began in 2025-01 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical study, designed as a double-blind, randomized, placebo-controlled trial, aims to investigate the potential of nicotinamide riboside (NR) to decelerate functional decline in the elderly frail population. In animal studies, NR, which is converted to nicotinamide adenine dinucleotide (NAD), has shown potential as a neuroprotective agent, with indications of protection against amyotrophic lateral sclerosis (ALS), Alzheimer's dementia, and Parkinson's disease. Furthermore, aging is commonly associated with decreased tissue NAD levels, a phenomenon linked to premature aging and a spectrum of age-related disorders, including cardiovascular diseases and cancers. Existing preclinical and clinical research highlights the promise of NAD replenishment through enhanced DNA repair, sirtuin activity, and improved mitochondrial function. The research center has conducted two phase II clinical trials on NR for Parkinson's disease (NAD-PARK and NR-SAFE), administering up to 3000 mg of NR daily. These trials have shown promising results, indicating NR's potential as a treatment that may alter the course of the disease and possibly as neuroprotective treatment in Parkinson's disease. The NAD age trial primarily aims to determine: * The efficacy of NAD therapy in improving clinical symptoms of frailty, evaluated through standardized physical and cognitive function tests. * The safety of administering 2000 mg NR daily in an elderly frail population. The study will include 100 individuals, classified as frail based on the Fried Frailty Phenotype. Participants will be randomly assigned to receive either 2000 mg of NR daily or a placebo. Over a 52-week period, participants will undergo: * Clinical evaluations, including actigraphy and questionnaires. * Cognitive assessments. * Bio sampling. * Magnetic resonance imaging (MRI). * Positron emission tomography (FDG-PET) scanning. The outcomes of this study could potentially demonstrate that NR effectively reduces signs of frailty, offering considerable advantages to the individuals affected, their families, and society as a whole.
Eligibility Criteria
Inclusion Criteria: * Participant must understand the nature of the study and be able to provide written, informed consent. * Male or female aged ≥ 75 years at baseline. * Fried Frailty Phenotype score ≥ 3 to identify frail individuals. * Montreal Cognitive Assessment (MoCA) at screening adjusted to age, gender, and educational level, with a threshold set at the 10th percentile (z-score ≤ -1.28). Exclusion Criteria: * Inability to provide informed consent. * Does not reside in a facility or institution. * Advanced disability, end-stage disease, presence of severe chronic illness and/or life expectancy of less than a year. * Inability to complete a 6-minute walk test (6MWT) and/or contraindications to the procedure (history of unstable angina or myocardial infarction within 30 days prior to the test). * Diagnosis of active malignancy in the last 2 years at baseline (exceptions include non-metastatic skin conditions and non-metastatic and/or treated prostate cancer with stable prostate-specific antigen (PSA) levels in six months prior to baseline). Specific considerations may apply depending on the type of cancer. * Significant neurological or psychiatric disorders, including but not limited to psychotic disorders, severe bipolar or unipolar depression, multiple sclerosis, uncontrolled seizure conditions, and neurodegenerative disorder. * A history of cerebrovascular events, excluding transient ischemic attack (TIA) that occurs more than 3 months prior to baseline. * Hospitalization or major surgery within 3 months prior to baseline. * Significant changes in medications or treatment plans made less than one month prior to baseline, judged by the site investigator to interfere with the subject's participation in the study. * Consumption of NAD precursor supplements (e.g., Nicotinamide riboside, nicotinamide mononucleotide or Vitamin B3), or related supplements within 6 months prior to baseline. * Elective surgeries scheduled during the study duration. * Concurrent participation in other clinical trials with interventions that could affect frailty measures. * Any medical history, at the discretion of the investigator, might hinder compliance with study procedures or increase risk to the participant.
Contact & Investigator
Charalampos Tzoulis, PhD
STUDY DIRECTOR
Haukeland University Hospital
Frequently Asked Questions
Who can join the NCT06208527 clinical trial?
This trial is open to participants of all sexes, aged 75 Years or older, studying Frailty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06208527 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06208527 currently recruiting?
Yes, NCT06208527 is actively recruiting participants. Contact the research team at charalampos.tzoulis@helse-bergen.no for enrollment information.
Where is the NCT06208527 trial being conducted?
This trial is being conducted at Bergen, Norway, Bergen, Norway.
Who is sponsoring the NCT06208527 clinical trial?
NCT06208527 is sponsored by Haukeland University Hospital. The principal investigator is Charalampos Tzoulis, PhD at Haukeland University Hospital. The trial plans to enroll 100 participants.